Skip Navigation
Skip to contents

KoreaMed

View Menu

Go to Home

Search

-Advanced Search   -Search Guidelines

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

71 results
Display

Email citations

Send Email
recaptcha 영역

Close

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

Gedallovich SM, Kwo PY

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Gedallovich SM, Kwo PY

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reply to correspondence on “Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity”

Komori A

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Nishida N

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

Kwo PY

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Lim SB, Cho HJ

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Ahmed A

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”

Lee HL, Jang JW

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Nguyen VH, Nguyen MH

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”

Incicco S, Piano S

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Ahn JC, Yang JD

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Dezhbord M, Kim KH

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Fukunaga S, Nakane T, Mukasa M, Takedatsu H, Kawaguchi T

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Zhu Y, Ma X, Ni W, Yeo YH, Shi J, Li J

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Lee CR, Park SG

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Bertoletti A, Tan AT

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Yu J

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Bae JH

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”

Cho EJ

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reply to correspondence on “Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis

Attia AM, Adetyan H, Yang JD

Cite
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr